NCT00678977 - A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 3, 2008

Primary Completion Date

March 30, 2010

Study Completion Date

June 30, 2011

Conditions

Lung Cancer, Non-Small Cell

Interventions

DRUG

Pazopanib (GW786034)

initial dose 400mg daily in 21-day cycles; increase in dose up to 800mg daily following evaluation of safety and tolerability

DRUG

Gemcitabine

Gemcitabine on Days 1 and 8 of each cycle; initial dose 600 mg/m2 increase to 1,000mg/m2 after evaluation of safety and tolerability; increase to 1250mg/m2 after evaluation of safety and tolerability

DRUG

Cisplatin

Cisplatin on Day 1 of each 21-day cycle initial dose 60mg/m2; increase to 80mg/m2 after evaluation of safety and tolerability

Trial Locations (2)

45122

GSK Investigational Site, Essen

NE4 6BE

GSK Investigational Site, Newcastle upon Tyne